Retatrutide and obstructive sleep apnea
New randomized Phase 3 findings report that investigational retatrutide substantially reduced obstructive sleep apnea severity in adults with obesity. This extends clinical investigation beyond weight loss to obesity-related complications.
Evidence level: Controlled human trial evidence. Results apply to the studied populations and outcomes; retatrutide remains investigational and is not FDA-approved.
RETATRUTIDE
Retatrutide is a once-weekly investigational triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. Unlike many compounds in the biohacking conversation, its weight-loss story is supported by large randomized trials. The biggest gap is no longer whether it can drive substantial weight loss—it is the leap from an investigational medicine in controlled trials to unapproved products sold outside that system.
Retatrutide targets three metabolic hormone pathways and has produced substantial weight loss in human clinical trials.
Still investigational.
Multiple positive Phase 3 trials have been reported. Retatrutide is not FDA approved, and Lilly says it plans an FDA submission in Q1 2027.
Clinical evidence check · October 2026
Retatrutide remains investigational and is not FDA approved. Distinguish peer-reviewed Phase 2 and published Phase 3 results from manufacturer topline press releases: positive TRIUMPH-2 and TRIUMPH-3 announcements are not themselves FDA authorization. Trial weight-loss results apply to enrolled populations and monitored investigational products; they do not establish the identity, safety, or effectiveness of products sold outside clinical trials. Lilly reported an intended U.S. submission in Q1 2027, not an approval date.
Lilly investigational status and trial overview ↗Lilly July 2026 topline announcement ↗
Three signals.
One molecule.
Retatrutide (LY3437943) is an investigational peptide that activates three metabolic hormone receptors: GIP, GLP-1 and glucagon.
The first two targets are familiar from the incretin-drug story. Adding glucagon receptor agonism creates a distinct “triple agonist” approach intended to influence appetite, glucose regulation and energy metabolism through a single molecule.
The signal is real.
In the published Phase 2 obesity trial, 338 adults were randomized to retatrutide or placebo. At 48 weeks, mean weight change reached 24.2% in the 12 mg group versus 2.1% with placebo. The most common adverse events were gastrointestinal, and dose-dependent heart-rate increases peaked at 24 weeks before declining.
Since then, the Phase 3 evidence record has matured. TRIUMPH-1 was published in the New England Journal of Medicine and TRIUMPH-2 was published in The Lancet on September 29, 2026. In TRIUMPH-2, 1,152 adults with obesity or overweight and type 2 diabetes were randomized to placebo or retatrutide 4, 9 or 12 mg for 80 weeks. The treatment-regimen estimand showed mean weight changes of −11.9%, −16.8% and −18.8%, respectively, versus −5.1% with placebo; Lilly’s efficacy estimand reported up to 20.8% at 12 mg. A1C fell by up to an average of 1.6 percentage points.
Different strengths. No head-to-head trial yet.
Cross-trial comparisons suggest a more nuanced story than “Retatrutide is better.” Tirzepatide has the stronger raw A1C result in the trials below; Retatrutide has produced the larger obesity weight-loss result.
Reta vs Tirz: what the data actually say
Separate trials, different populations, baselines, durations and estimands. This is not a randomized Retatrutide-vs-Tirzepatide comparison.
A1C reduction · type 2 diabetes trials
Retatrutide: TRIUMPH-2, 80 weeks, baseline mean A1C 7.71%. Tirzepatide: SURPASS-2, 40 weeks, baseline mean A1C 8.28%. Baseline A1C affects how much room there is to fall.
Mean weight loss · obesity trials without diabetes
Retatrutide: TRIUMPH-1 efficacy estimand at 80 weeks. Tirzepatide: SURMOUNT-5 maximum tolerated dose at 72 weeks. Separate trials—not proof of superiority.
Open the Tirzepatide evidence profile →
Where the data are strong—and where the story runs ahead.
Here, The Gap changes shape.
Exceptional attention
Online discussion centers on weight loss, appetite suppression, GI effects, fatigue, heart rate, sleep and comparisons with semaglutide and tirzepatide.
- Large weight-loss expectations
- Frequent comparison with approved incretin drugs
- Substantial interest in products sold before approval
- Anecdotes still cannot establish prevalence, safety or product authenticity
Substantial
Retatrutide has randomized controlled Phase 2 evidence and multiple reported positive Phase 3 trials in obesity and related cardiometabolic populations.
- Published randomized obesity Phase 2 trial
- Published randomized type 2 diabetes Phase 2 trial
- Multiple positive Phase 3 topline readouts
- Regulatory approval has not yet occurred
Weight loss: comparatively narrow—the clinical efficacy signal is strong. Unapproved access, product equivalence and broader claims: much wider. Evidence that Lilly’s investigational medicine works in controlled trials does not validate products marketed online as “retatrutide.”
What people are actually reporting.
Recurring community-use patterns are visible around Retatrutide. We document those patterns here without turning them into a clinical recommendation.
Community reports frequently cluster around once-weekly use in the low-single-digit milligram range, often after gradual increases. Higher weekly amounts are also widely discussed, especially by users following the investigational trial titration framework.
Retatrutide has a defined investigational clinical-trial dosing program, but it is not FDA approved. Phase 2 obesity research studied once-weekly doses up to 12 mg with stepwise escalation. Community use of unapproved products is not evidence of product identity, purity, safety or equivalence to trial material.
Effective in trials does not mean approved—or risk-free.
Retatrutide has a much deeper human safety dataset than many compounds in the Peptide Index, but its benefit-risk profile is still undergoing development and regulatory evaluation.
In Phase 2 obesity research, gastrointestinal events were the most common adverse events and were dose-related, generally mild to moderate. Dose-dependent increases in heart rate were also observed. The peer-reviewed TRIUMPH-2 Phase 3 publication adds two notable controlled safety signals: hypotension occurred in 1%, 5% and 6% of the 4, 9 and 12 mg groups versus less than 1% with placebo, while dysesthesia occurred in 4%, 6% and 7% versus 1% with placebo. Gastrointestinal events remained the most frequently reported adverse events.
A fast-moving evidence story.
Research
TRIUMPH-2 moved from topline result to peer-reviewed Phase 3 evidence.
The Lancet published the randomized 1,152-participant trial. Beyond substantial weight loss and improved glycemic control, the full safety data make dysesthesia and hypotension controlled-trial signals rather than community-only observations.
Research
TRIUMPH-2 and TRIUMPH-3 added two more positive Phase 3 readouts.
Lilly reported mean weight reductions up to 20.8% at 80 weeks in adults with obesity/overweight and type 2 diabetes and up to 22.6% in adults with severe obesity and established cardiovascular disease. Lilly also said it now has the clinical package to support planned global submissions.
Regulatory
FDA sharpened its warning around unapproved retatrutide.
FDA says retatrutide cannot be used in compounding under federal law and has warned companies involved in marketing, distributing or repackaging unapproved retatrutide.
Research
TRIUMPH-4 delivered the first successful Phase 3 readout.
In adults with obesity or overweight and knee osteoarthritis, Lilly reported mean weight loss up to 28.7% at 68 weeks along with substantial improvement in WOMAC knee-pain scores.
Show the receipts.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| Obesity Phase 2 · PMID 37366315 | Randomized, double-blind, placebo-controlled · n=338 | Strong dose-dependent weight-loss efficacy signal through 48 weeks; characterizes common adverse events. | Does not establish long-term outcomes or regulatory approval. |
| Type 2 diabetes Phase 2 · PMID 37385280 | Randomized, double-blind, placebo + active-controlled · n=281 | Supports glycemic and weight effects in adults with type 2 diabetes. | Does not substitute for Phase 3 or regulatory review. |
| TRIUMPH-4 | Phase 3 · obesity/overweight + knee OA | Positive topline efficacy and safety readout; up to 28.7% mean weight loss reported at 68 weeks. | Topline company report is not the same as full peer-reviewed publication. |
| TRIUMPH-2 · PMID 42810372 | Phase 3 · randomized, double-blind, placebo-controlled · n=1,152 | Peer-reviewed evidence in obesity/overweight plus type 2 diabetes; adds detailed efficacy, glycemic and safety data including dysesthesia and hypotension. | Does not establish superiority to tirzepatide or regulatory approval. |
| TRIUMPH-3 | Phase 3 · severe obesity + established cardiovascular disease | Extends the positive efficacy signal into a high-risk cardiovascular population. | Topline results should remain distinct from a full peer-reviewed publication. |
| FDA unapproved GLP-1 guidance | Regulatory | Clarifies that retatrutide is unapproved and cannot legally be used in compounding. | Does not negate clinical-trial evidence for Lilly’s investigational product. |
Read deeper.
Follow the evidence.
Metabolic Health
Explore the biology and evidence behind compounds connected to obesity, glucose regulation and cardiometabolic health.
Retatrutide vs Tesamorelin
Compare two very different metabolic stories: triple-agonist obesity research versus an approved therapy with a specific indication.
Community Pulse
See what people are discussing without confusing online experience with clinical evidence.
BPC-157
Contrast retatrutide’s substantial clinical evidence with one of the widest evidence gaps in recovery culture.